Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1546 to 1560 of 2008 results for nice guidelines

  1. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Withdrawn guidance

  2. Breast reconstruction using lipomodelling after breast cancer treatment (HTG280)

    Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.

    HealthTech guidance
    Published
    23 January 2012
    View recommendations

    Sections for HTG280

  3. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  4. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  5. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA195

  6. Transobturator foramen procedures for stress urinary incontinence (IPG107)

    The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transobturator foramen procedures for stress incontinence in January 2005. This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG40. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.

    Withdrawn guidance

  7. Idiopathic overactive bladder syndrome: botulinum toxin A (ESNM2)

    This evidence summary has been replaced by NICE guideline CG171.

    Withdrawn advice

  8. Balloon thermal endometrial ablation (using data from Cavaterm and Gynecare as specified by SERNIP) (IPG6)

    This guidance has been updated and replaced by NICE guideline CG44.

    Withdrawn guidance

  9. Transurethral radiofrequency needle ablation of the prostate (IPG15)

    This guidance has been updated and replaced by NICE guideline CG97.

    Withdrawn guidance

  10. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

    Withdrawn advice

  11. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

    This advice has been updated and replaced by NICE guideline NG221.

    Withdrawn advice

  12. Clostridium difficile infection: fidaxomicin (ESNM1)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  13. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Withdrawn advice

  14. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  15. Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection (MIB247)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice